Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nefopam is a centrally acting, non-opioid analgesic used for the relief of moderate to severe pain, including acute and chronic pain such as post-operative pain, dental pain, musculoskeletal pain, acute traumatic pain, and cancer-related pain. It is structurally related to orphenadrine and diphenhydramine. Nefopam's mechanism of action is not fully understood but involves inhibition of the reuptake of serotonin, noradrenaline (norepinephrine), and dopamine in the central nervous system. It also blocks sodium and calcium channels in the CNS. Unlike opioids, it does not cause respiratory depression or significant abuse potential but can cause side effects such as nausea, dizziness, sweating, tachycardia, anticholinergic effects (e.g., dry mouth), confusion (especially in elderly), hallucinations at higher doses or overdose. Nefopam may be used when other analgesics are ineffective or contraindicated[2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nefopam.